MedPath

Aspacytarabine

Generic Name
Aspacytarabine
Drug Type
Small Molecule
Chemical Formula
C13H18N4O8
CAS Number
2098942-53-9
Unique Ingredient Identifier
JL7V54Z2BR
Clinical Trials
Related News

A Phase I/II Dose Escalation and Expansion Study of BST-236 Plus Venetoclax in Patients With Unfit Newly Diagnosed AML

Phase 1
Recruiting
Conditions
AML, Adult
Interventions
First Posted Date
2022-08-16
Last Posted Date
2023-04-04
Lead Sponsor
BioSight Ltd.
Target Recruit Count
80
Registration Number
NCT05503355
Locations
🇺🇸

Northwestern Memorial Hospital, Chicago, Illinois, United States

🇺🇸

The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

🇺🇸

University of Virginia Cancer Center, Charlottesville, Virginia, United States

BST-236 as a Single Agent in Adults With Relapsed or Refractory AML or HR-MDS

Phase 2
Completed
Conditions
Myelodysplastic Syndromes
Acute Myeloid Leukemia
Interventions
First Posted Date
2021-04-01
Last Posted Date
2025-05-18
Lead Sponsor
Groupe Francophone des Myelodysplasies
Target Recruit Count
38
Registration Number
NCT04827719
Locations
🇫🇷

CHU d'Angers, Angers, France

🇫🇷

CHU de Bordeaux Haut-Lévèque, Bordeaux, France

🇫🇷

CHU Amiens, Amiens, France

and more 14 locations

Phase 2, Open-Label, Single Arm Study, With BST-236 in Adults With R/R AML or Higher-Risk MDS

Phase 2
Conditions
MDS
Relapse/Recurrence
AML, Adult
Refractory Acute Myeloid Leukemia
Interventions
First Posted Date
2021-02-11
Last Posted Date
2023-03-09
Lead Sponsor
BioSight Ltd.
Target Recruit Count
40
Registration Number
NCT04749355
Locations
🇺🇸

Seattle Cancer Care Alliance, Seattle, Washington, United States

🇺🇸

Ochsner LSU Health Shreveport - Academic Medical Center, Shreveport, Louisiana, United States

🇺🇸

University of Virginia Cancer Center, Charlottesville, Virginia, United States

and more 1 locations

Efficacy and Safety of BST-236 in Newly Diagnosed Acute Myeloid Leukemia Patients, Unfit for Standard Induction Therapy

Phase 2
Completed
Conditions
Acute Myeloid Leukemia
Interventions
First Posted Date
2018-02-19
Last Posted Date
2023-07-27
Lead Sponsor
BioSight Ltd.
Target Recruit Count
66
Registration Number
NCT03435848
Locations
🇺🇸

Abramson Cancer Center, Philadelphia, Pennsylvania, United States

🇮🇱

Rambam medical center hematology department, Haifa, Israel

🇺🇸

Baylor Scott & White Research Institute Dallas Texas, Dallas, Texas, United States

and more 13 locations

Study Evaluating the Safety and Efficacy of Astarabine in Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

Phase 1
Completed
Conditions
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Interventions
First Posted Date
2015-09-09
Last Posted Date
2017-09-27
Lead Sponsor
BioSight Ltd.
Target Recruit Count
20
Registration Number
NCT02544438
Locations
🇮🇱

Rambam medical center hematology department, Haifa, Israel

🇮🇱

Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy